

1 **The role of COVID-19 vaccines in preventing post COVID-19**
2 **thromboembolic and cardiovascular complications: a multinational**
3 **cohort study**

4
5 Author list

6 Núria Mercadé-Besora^{1,2,3}, BA, nmercade@idiapjgol.org

7 Xintong Li¹, MSc, xintong.li@ndorms.ox.ac.uk

8 Raivo Kolde, PhD⁴, raivo.kolde@ut.ee

9 Nhung TH Trinh, PhD⁵, nhung.trinh@farmasi.uio.no

10 Maria T. Sanchez-Santos, MSc¹, maria.sanchez@ndorms.ox.ac.uk

11 Wai Yi Man, MSc¹, waiyi.man@ndorms.ox.ac.uk

12 Elena Roel, PhD³, eroel@idiapjgol.org

13 Carlen Reyes³, creyes@idiapjgol.org

14 Antonella Delmestri, PhD¹, antonella.delmestri@ndorms.ox.ac.uk

15 Hedvig ME Nordeng, PhD^{5,6}, h.m.e.nordeng@farmasi.uio.no

16 Anneli Uusküla, PhD⁷, anneli.uuskula@ut.ee

17 Talita Duarte-Salles, PhD^{3,8}, tduarte@idiapjgol.org

18 Clara Prats, PhD², clara.prats@upc.edu

19 Daniel Prieto-Alhambra, PhD^{1,8,9}, daniel.prietoalhambra@ndorms.ox.ac.uk

20 Annika M Jödicke, PhD^{*1}, annika.jodicke@ndorms.ox.ac.uk

21 Martí Català, PhD^{*1}, marti.catalasabate@ndorms.ox.ac.uk

22

23 ¹ Pharmaco- and Device Epidemiology Group, Health Data Sciences, Botnar Research Centre, NDORMS, University of
24 Oxford, United Kingdom

25 ² Department of Physics, Universitat Politècnica de Catalunya, Barcelona, Spain

26 ³ Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol),
27 Barcelona, Spain

28 ⁴ Institute of Computer Science, University of Tartu, Tartu, Estonia

29 ⁵ Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and
30 Natural Sciences, University of Oslo, Oslo, Norway

31 ⁶ Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway

32 ⁷ Department of Family Medicine and Public Health, University of Tartu, Tartu, Estonia

33 ⁸ Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands

34 ⁹ Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

35

36 *MC and AMJ share senior authorship

37 Corresponding author:

38 Prof. Daniel Prieto-Alhambra

39 Botnar Research Centre, Windmill Road, OX3 7LD, Oxford, United Kingdom

40

41 Word count: 3000

42

43 **Key Points**

44 **Question**

45 What is the impact of COVID-19 vaccination to prevent cardiac complications and
46 thromboembolic events following a SARS-CoV-2 infection?

47 **Findings**

48 Results from this multinational cohort study showed that COVID-19 vaccination reduced risk
49 for acute and subacute COVID-19 heart failure, as well as venous and arterial
50 thromboembolic events following SARS-CoV-2 infection.

51 **Meaning**

52 These findings highlight yet another benefit of vaccination against COVID-19, and support
53 the recommendations for COVID-19 vaccination even in people at high cardiovascular risk.

54 **Abstract**

55 **Importance**

56 The overall effects of vaccination on the risk of cardiac, and venous and arterial
57 thromboembolic complications following COVID-19 remain unclear.

58 **Objective**

59 We studied the association between COVID-19 vaccination and the risk of acute and
60 subacute COVID-19 cardiac and thromboembolic complications.

61 **Design**

62 Multinational staggered cohort study, based on national vaccination campaign rollouts.

63 **Setting**

64 Network study using electronic health records from primary care records from the UK,
65 primary care data linked to hospital data from Spain, and national insurance claims from
66 Estonia.

67 **Participants**

68 All adults with a prior medical history of ≥ 180 days, with no history of COVID-19 or previous
69 COVID-19 vaccination at the beginning of vaccine rollout were eligible.

70 **Exposure**

71 Vaccination status was used as a time-varying exposure. Vaccinated individuals were
72 classified by vaccine brand according to the first dose received.

73 **Main Outcomes**

74 Post COVID-19 complications including myocarditis, pericarditis, arrhythmia, heart failure
75 (HF), venous (VTE) and arterial thromboembolism (ATE) up to 1 year after SARS-CoV-2
76 infection.

77 **Measures**

78 Propensity Score overlap weighting and empirical calibration based on negative control
79 outcomes were used to minimise bias due to observed and unobserved confounding,
80 respectively. Fine-Gray models were fitted to estimate sub-distribution Hazard Ratios (sHR)
81 for each outcome according to vaccination status. Random effect meta-analyses were
82 conducted across staggered cohorts and databases.

83 **Results**

84 Overall, 10.17 million vaccinated and 10.39 million unvaccinated people were included.
85 Vaccination was consistently associated with reduced risks of acute (30-day) and subacute
86 post COVID-19 VTE and HF: e.g., meta-analytic sHR 0.34 (95%CI, 0.27-0.44) and 0.59 (0.50-
87 0.70) respectively for 0-30 days, sHR 0.58 (0.48 - 0.69) and 0.71 (0.59 - 0.85) respectively for
88 90-180 days post COVID-19. Additionally, reduced risks of ATE, myocarditis/pericarditis and
89 arrhythmia were seen, but mostly in the acute phase (0-30 days post COVID-19).

90 **Conclusions**

91 COVID-19 vaccination reduced the risk of post COVID-19 complications, including cardiac
92 and thromboembolic outcomes. These effects were more pronounced for acute (1-month)
93 post COVID-19 outcomes, consistent with known reductions in disease severity following
94 breakthrough vs unvaccinated SARS-CoV-2 infection.

95 **Relevance**

96 These findings highlight the importance of COVID-19 vaccination to prevent cardiovascular

97 outcomes after COVID-19, beyond respiratory disease.

98

99 **Keywords**

100 - Subacute COVID-19 complications

101 - Pharmacoepidemiology

102 - Public health

103 - Cohort study

104 - COVID-19 vaccines

105 - Cardiovascular diseases

106

107 **Introduction**

108 COVID-19 vaccines were approved under emergency authorisation as from December 2020.

109 They showed high effectiveness against SARS-CoV-2 infection, COVID-19 related

110 hospitalisation and death (1–5). Nonetheless, concerns were raised after research findings

111 suggested a potential association between adenovirus -based COVID-19 vaccines and

112 unusual thromboembolic events (6–10). More recently, mRNA -based vaccines were found

113 to be associated with risk of rare myocarditis events, especially among male teenagers and

114 young adults (11–16).

115 On the other hand, it is well-known that SARS-CoV-2 infection can trigger cardiac and

116 thromboembolic complications (17–19). Previous studies have showed that while slowly

117 decreasing over time, risk for serious complications remain high for up to a year after

118 infection (20,21). While acute and subacute cardiac and thromboembolic complications

119 following SARS-CoV-19 are rare, they present a substantial burden to the affected patients.

120 Given the global extension of the pandemic, the absolute number of cases could become

121 substantial.

122 Recent studies suggest that COVID-19 vaccination could potentially protect against cardiac

123 and thromboembolic complications attributable to COVID-19 (22–24). However, most of

124 those focussed on relatively short-term complications (up to 30 (22) and 180 (23) days after

125 infection) and were conducted in specific populations (ambulatory infections (22) and US

126 Veterans (23)).

127 Evidence is still scarce to whether the additive effect of COVID-19 vaccines protecting 1)

128 against SARS-CoV-2 infection and 2) reducing post COVID-19 cardiac and thromboembolic

129 outcomes, outweighs any risks of these complications potentially associated with
130 vaccination.
131 We leveraged large representative data sources from 3 European countries to assess the
132 overall effect of COVID-19 vaccines on the risk of acute and subacute post COVID-19
133 complications including venous thromboembolism (VTE), arterial thromboembolism (ATE),
134 and cardiac events. Additionally, we studied the comparative effects of ChAdOx1 (adenovirus
135 -based) vs BNT162b2 (mRNA -based) on the risk of these same outcomes.

136

137 **Methods**

138 **Data Sources**

139 We used four routinely-collected population-based healthcare datasets from three European
140 countries: the UK, Spain, and Estonia.

141 For the UK, we utilized data from two primary care databases, namely Clinical Practice
142 Research Datalink, CPRD AURUM (25) and CPRD GOLD (26), which currently cover 3.1 million
143 and 13 million active participants, respectively. Additionally, Spanish data was provided by
144 the Information System for Research in Primary Care (SIDIAP) (27) which encompasses
145 primary care records from around 75% of the population in the region of Catalonia, and it
146 was linked to hospital admissions data (Conjunt Mínim Bàsic de Dades d'Alta Hospitalària).
147 Finally, the CORIVA cohort was retrieved from the Estonian national health insurance claims
148 database, covering around 440 thousand participants consisting of a random sample of the
149 population plus all COVID-19 cases identified during the first year of the pandemic. CORIVA
150 was linked to death registry and all COVID-19 testing from the national health information
151 system.

152 Databases included socio-demographic information, diagnoses, measurements,
153 prescriptions, and secondary care referrals. Further, all databases were linked to vaccine
154 registries, including records of all administered vaccines from all healthcare settings. Data
155 availability for CPRD GOLD ended in 12/2021, AURUM in 01/2022, SIDIAP in 06/2022, and
156 CORIVA in 12/2022.

157 All four databases were mapped to the Observational Medical Outcomes Partnership
158 (OMOP) Common Data Model (CDM) (28) to facilitate federated analytics.

159 **Multinational network staggered cohort study: Study design and participants**

160 The study considered vaccination as a time-varying exposure using a staggered cohort
161 design. Vaccine rollout phases were grouped in four different stages, each one with country-
162 specific dates and inclusion criteria.

163 Source population comprised all adults registered in the respective database for at least 180
164 days at the start of the study (04/01/2021 for CPRD GOLD and AURUM, 20/02/2021 for
165 SIDIAP, and 28/01/2021 for CORIVA). Subsequently, each staggered cohort included
166 individuals eligible for vaccination during the enrolment period who were not previously
167 vaccinated against or infected with SARS-CoV-2. Cohort 1 enrolled elderly population,
168 whereas cohort 2 comprised individuals at risk for severe COVID-19. Cohort 3 comprised
169 people aged ≥ 40 , and cohort 4 included predominantly younger people (≥ 18).

170 People receiving a first vaccine dose within enrolment period were allocated to the
171 vaccinated cohort (VC), and their index date was the date of the first vaccine dose.

172 Individuals who did not receive a vaccine dose comprised the unvaccinated cohort (UVC),
173 and their index date was sorted within enrolment period, based on the distribution of index
174 dates in the VC. Individuals infected with SARS-CoV-2 before index date were excluded.

175 Follow-up of individuals was until the earliest of: end of available data, death, change in
176 exposure status (first vaccine dose for UVC), or outcome of interest.
177 Supplementary Figures S1-2 and Table S1 provide more details on cohort definitions,
178 enrolment periods and inclusion criteria for each country. The proposed staggered cohort
179 study design was used in previous work and is published in detail elsewhere (29).

180 **COVID-19 vaccination**

181 All vaccines approved within study periods from 01/2021 to 07/2021, namely ChAdOx1
182 [Oxford/AstraZeneca], BNT162b2 [BioNTech/Pfizer], Ad26.COV2.S [Janssen], and mRNA-1273
183 [Moderna] were included for this study.


184 **Post COVID-19 outcomes of interest**

185 Outcomes of interest in the study were defined as a SARS-CoV-2 infection followed by a
186 record of a pre-defined thromboembolic or cardiac event of interest within a year after
187 infection, in those individuals with no record of the same clinical event in the 6 months
188 before COVID-19. Outcome date was set as the corresponding SARS-CoV-2 infection date.
189 COVID-19 disease was identified from either a positive SARS-CoV-2 test (PCR/ antigen), or a
190 clinical COVID-19 diagnosis, with no record of COVID-19 in the previous 6 weeks. This wash-
191 out period was imposed to identify “new” infections and exclude re-recordings of the same
192 COVID-19 episode.

193 Events of interest after COVID-19 were selected based on previous studies (21,22,30). These
194 were ischemic stroke (IS), haemorrhagic stroke (HS), transient ischemic attack (TIA),
195 ventricular arrhythmia or cardiac arrest (VACA), myocarditis or pericarditis (MP), myocardial
196 infarction (MI), heart failure (HF), pulmonary embolism (PE) and deep vein thrombosis
197 (DVT). We used two composite outcomes: 1) VTE, as an aggregate of PE and DVT, and 2)
198 ATE, as a composite of IS, TIA, and MI. To avoid re-recording of the same complication we

199 imposed a wash-out period of 90 days between records. Phenotypes for these complications
200 were based on previously published studies (31,32).
201 Further, outcomes were ascertained in four different time periods following SARS-CoV-2
202 infection: the first period described the acute infection phase, i.e. 0 to 30 days after COVID-
203 19, whereas the later periods, i.e. 31 to 90 days, 91 to 180 days, and 181 to 365 days
204 illustrate the subacute phase (Figure 1).

205 **Figure 1: Study outcome design.** Study outcomes of interest are defined as a COVID-19 infection followed by one of the complications in the figure, within year after
 206 infection. Outcomes were ascertained in four different time windows after SARS-CoV-2 infection: 0-30 days (namely the acute phase), 31-90 days, 91-180 days, and 181-365
 207 days (these last three comprise the subacute phase).



208

209 **Negative Control Outcomes**

210 Negative control outcomes (NCO) refer to outcomes which investigators believe they are not
211 associated (causal relation) with the exposure, and share the same causal or bias structure
212 with the exposure and outcome of interest (33). The expected occurrence of events should
213 be similar in the compared cohorts, otherwise it may indicate a source of unobserved bias.
214 The study used 43 different NCO from previous work assessing vaccine effectiveness (34,35)
215 to detect residual confounding.

216 **Statistical analysis**

217 Federated network analyses

218 A template for an analytical script was developed, and subsequently tailored to include the
219 country-specific aspects (e.g. dates, priority groups) for the vaccination rollout. The specific
220 R code was then executed locally in each database. Only aggregated data was shared and
221 person counts <5 were clouded.

222 Propensity Score Weighting

223 Large-Scale Propensity Scores (PS) were calculated to estimate the likelihood of a person to
224 receive the vaccine based on their demographic and health-related (e.g. conditions,
225 medication) characteristics prior to the index date. PS were then used to minimise observed
226 confounding by creating a weighted population (based on Overlap Weights (36)) in which
227 individuals contributed with a different weight based on their PS and vaccination status.
228 Variables included in the PS comprised age, sex, location, index date, prior observation time
229 in the database, number of previous outpatient visits, and previous SARS-CoV-2 PCR/antigen
230 tests. Regional vaccination, testing and COVID-19 incidence rates were also forced into PS
231 equation for CPRD AURUM and GOLD (37) and SIDIAP (38). In addition, conditions and

232 prescriptions within 0-30 days, 31-180 days, and 181-anytime (latter window only for
233 conditions) before index date, with a prevalence of >0.5% and predictive of vaccination
234 based on LASSO regression, were included to the PS model.
235 PS were estimated for each staggered cohort and analysis separately. We considered that
236 covariate balance was achieved if Absolute Standardised Mean Differences (ASMD) were
237 ≤ 0.1 after weighting (39). Baseline characteristics (e.g. age, sex, prior history, general health
238 conditions) were reported.

239 Effect estimation

240 To account for the competing risk of death associated with COVID-19, Fine-and-Gray models
241 (40) were utilized to calculate subdistribution Hazard Ratios (sHR). Subsequently, sHR and
242 confidence intervals were empirically calibrated from NCO estimates (41) to account for
243 unmeasured confounding.

244 For each outcome, treatment estimates from the four staggered studies were pooled using
245 random effect meta-analysis (42), both separately for each database and across all four
246 databases.

247 **Sensitivity analysis**

248 Sensitivity analyses were used to test the effect of two approaches in the main analysis: first,
249 we censored follow-up for vaccinated people at the time when they received their second
250 vaccine dose. Second, we captured only the first post COVID-19 outcome within the year
251 after infection. Supplementary Figure S3 depicts follow-up for the analyses.

252 Further, we compared vaccinated groups by vaccine brand, namely, BNT162b2 vs. ChAdOx1.

253 **Data and code availability**

254 All analytic code for the study is available at ([https://github.com/oxford-](https://github.com/oxford-pharmacoepi/vaccineEffectOnPostCovidCardiacThromboembolicEvents)
255 [pharmacoepi/vaccineEffectOnPostCovidCardiacThromboembolicEvents](https://github.com/oxford-pharmacoepi/vaccineEffectOnPostCovidCardiacThromboembolicEvents)). The repository also

256 contains code lists for vaccines, COVID-19 tests and diagnoses, cardiac and thromboembolic
257 events, NCO, and health conditions to prioritize patients for vaccination in each country.
258 Analyses were conducted using R 4.2.3.

259

260 **Results**

261 All aggregated results are available via a web application (<https://dpa-pde-oxford.shinyapps.io/PostCovidComplications/>).

263 We included over 10.17 million vaccinated individuals (1,618,395 from CPRD
264 GOLD; 5,729,800 from CPRD AURUM; 2,744,821 from SIDIAP and 77,603 from CORIVA), and
265 10.39 million unvaccinated (1,640,371; 5,860,564; 2,588,518 and 302,267, respectively).
266 Supplementary Figures S4-7 illustrate flowcharts in each database.

267 Adequate covariate balance was achieved after PS weighting in most studies: CORIVA (all
268 cohorts) and SIDIAP (cohorts 1 and 4) did not contribute to ChAdOx1 sub-analysis due to
269 sample size and covariate unbalance. ASMD results are accessible in the web application.

270 NCO analyses suggested residual bias despite PS weighting, with a majority of NCO
271 associated positively with vaccination. Therefore, calibrated estimates are reported in this
272 manuscript. Uncalibrated effect estimates and NCO analyses are available in the web
273 interface.

274 **Population characteristics**

275 Table 1 presents baseline characteristics for the weighted populations in CPRD AURUM, for
276 illustrative purposes. Supplementary Tables S2-26 summarise baseline characteristics for
277 weighted and unweighted populations for each database and comparison. Across databases

278 and cohorts, populations followed similar patterns: cohort 1 represented the eldest
279 population (around 80 years old) with predominant female population (60%). Age median
280 lowered to 30-40 years in cohort 4, which was more balanced regarding sex. Overall,
281 weighted populations showed adequate balance (ASMD < 0.1) in all baseline characteristics.

282
283

Table 1: Characteristics of weighted populations in CPRD AURUM, database, stratified by staggered cohort and exposure status. Exposure is any COVID-19 vaccine.

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
N (individuals)	154,864	154,245		420,707	420,931		463,495	462,463		818,917	827,124	
Age, median [Q25-Q75]	80 [76-84]	80 [76-84]	0.000	58 [44-67]	58 [44-67]	0.005	50 [41-58]	52 [40-58]	0.003	34 [26-42]	34 [26-42]	0.004
Sex: Female, N(%)	88,349 (57%)	87,639 (57%)	0.005	248,156 (59%)	249,561 (59%)	0.006	245,248 (53%)	245,600 (53%)	0.004	351,435 (43%)	358,688 (43%)	0.009
Years of prior history^a, median [Q25-Q75]	24 [10-35]	24 [10-36]	0.006	18 [8-29]	18 [8-29]	0.003	14 [6-24]	14 [7-24]	0.008	8 [4-17]	7 [3-18]	0.001
Number visits, median [Q25-Q75]	10 [5-18]	10 [6-17]		8 [3-15]	8 [5-14]		4 [1-11]	6 [3-11]		2 [0-6]	2 [0-6]	
Number pcrs, median [Q25-Q75]	0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]		0[0-0]	0[0-0]	
Comorbidities^b, N(%)												
Anxiety	23,200 (15%)	22,789 (15%)	0.006	94,390 (22%)	91,644 (22%)	0.016	92,820 (20%)	90,807 (20%)	0.010	123,055 (15%)	125,202 (15%)	0.003
Asthma	16,978 (11%)	16,663 (11%)	0.005	95,770 (23%)	94,550 (22%)	0.007	79,642 (17%)	78,266 (17%)	0.007	63,687 (8%)	61,472 (7%)	0.013
Chronic kidney disease	36,149 (23%)	36,046 (23%)	0.001	28,181 (7%)	29,756 (7%)	0.015	10,283 (2%)	10,577 (2%)	0.005	3,840 (0%)	3,572 (0%)	0.006
COPD	13,385 (9%)	13,181 (9%)	0.003	17,447 (4%)	17,999 (4%)	0.006	6,062 (1%)	5,754 (1%)	0.006	1,901 (0%)	1,918 (0%)	0.000
Dementia	9,483 (6%)	8,517 (6%)	0.026	4,182 (1%)	3,879 (1%)	0.007	1,361 (0%)	1,392 (0%)	0.001	276 (0%)	495 (0%)	0.012
Depressive disorder	18,632 (12%)	18,547 (12%)	0.000	85,280 (20%)	81,945 (19%)	0.020	81,891 (18%)	79,804 (17%)	0.011	94,373 (12%)	97,053 (12%)	0.007
Diabetes	29,365 (19%)	28,831 (19%)	0.007	49,408 (12%)	48,562 (12%)	0.006	26,616 (6%)	28,628 (6%)	0.019	12,787 (2%)	12,539 (2%)	0.004

	Cohort 1			Cohort 2			Cohort 3			Cohort 4		
	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD	Unvaccinated	Vaccinated	ASMD
GERD	8,718 (6%)	8,515 (6%)	0.005	19,907 (5%)	18,924 (4%)	0.011	15,646 (3%)	14,982 (3%)	0.008	13,882 (2%)	13,893 (2%)	0.001
Heart failure	9,349 (6%)	8,851 (6%)	0.013	7,284 (2%)	6,502 (2%)	0.015	2,660 (1%)	2,470 (1%)	0.005	930 (0%)	816 (0%)	0.005
Hypertension	81,563 (53%)	80,806 (52%)	0.006	97,707 (23%)	98,193 (23%)	0.002	54,649 (12%)	55,798 (12%)	0.008	22,925 (3%)	24,450 (3%)	0.009
Hypothyroidism	15,125 (10%)	15,098 (10%)	0.001	25,579 (6%)	25,962 (6%)	0.004	17,162 (4%)	17,580 (4%)	0.005	12,427 (2%)	12,641 (2%)	0.001
Malignant neoplastic disease	33,467 (22%)	33,024 (21%)	0.005	30,194 (7%)	35,085 (8%)	0.043	14,815 (3%)	14,140 (3%)	0.008	6,447 (1%)	5,766 (1%)	0.011
Myocardial infarction	7,824 (5%)	7,731 (5%)	0.002	9,964 (2%)	11,319 (3%)	0.020	3,787 (1%)	3,664 (1%)	0.003	1,315 (0%)	1,069 (0%)	0.008
Osteoporosis	15,275 (10%)	15,373 (10%)	0.003	10,626 (3%)	10,718 (3%)	0.001	4,113 (1%)	4,131 (1%)	0.001	1,376 (0%)	1,472 (0%)	0.002
Pneumonia	8,573 (6%)	7,621 (5%)	0.027	11,355 (3%)	10,691 (3%)	0.010	6,651 (1%)	6,545 (1%)	0.002	5,144 (1%)	5,151 (1%)	0.001
Rheumatoid arthritis	3,066 (2%)	3,092 (2%)	0.002	6,198 (1%)	6,570 (2%)	0.007	2,355 (1%)	3,111 (1%)	0.021	1,201 (0%)	859 (0%)	0.012
Stroke	7,667 (5%)	7,047 (5%)	0.018	8,041 (2%)	8,794 (2%)	0.013	3,518 (1%)	3,293 (1%)	0.006	1,496 (0%)	1,305 (0%)	0.006
Venous thromboembolism	9,589 (6%)	9,241 (6%)	0.008	11,836 (3%)	12,475 (3%)	0.009	6,503 (1%)	8,075 (2%)	0.028	4,661 (1%)	2,441 (0%)	0.042

284 The 4 cohorts represent vaccine rollout periods.

285 ^aCalculated as the days of previous observation in the database before index date.

286 ^bAssessed anytime before index date. ASMD = Absolute standardized mean difference, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease

287 **COVID-19 vaccination and post COVID-19 complications**

288 Table 2 shows the incidence of post COVID-19 VTE, ATE and HF, the 3 most common post
289 COVID-19 conditions among the studied. Outcome counts are presented separately for the
290 0-30, 31-90, 91-180, and 181-365 days after SARS-CoV-2 infection. Supplementary Tables
291 S27-37 include all studied complications, also for the different sensitivity and sub-analyses.
292 Similar incidence patterns were observed across all analyses: higher rates in the elderly
293 populations (cohort 1) and decreasing frequency with time after infection in all cohorts.

294
295

Table 2: Number of records (and risk per 10,000 individuals) for acute and subacute COVID-19 cardiac and thromboembolic complications, across cohorts and databases for any COVID-19 vaccination.

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
Cohort 1			N = 346,674	N = 552,602	N = 23,982	N = 26,736	N = 169,100	N = 118,507	N = 223,962	N = 89,941
	0 to 30 days	VTE	154 (4.44)	117 (2.12)	93 (38.78)	36 (13.46)	15 (0.89)	8 (0.68)	251 (11.21)	96 (10.67)
		ATE	57 (1.64)	70 (1.27)	128 (53.37)	50 (18.70)	8 (0.47)	7 (0.59)	350 (15.63)	208 (23.13)
		HF	135 (3.89)	198 (3.58)	439 (183.05)	199 (74.43)	21 (1.24)	9 (0.76)	1,205 (53.80)	640 (71.16)
	31 to 90 days	VTE	32 (0.92)	40 (0.72)	32 (13.34)	12 (4.49)	< 5	< 5	92 (4.11)	46 (5.11)
		ATE	15 (0.43)	43 (0.78)	33 (13.76)	23 (8.60)	< 5	< 5	222 (9.91)	130 (14.45)
		HF	72 (2.08)	113 (2.04)	143 (59.63)	86 (32.17)	8 (0.47)	8 (0.68)	493 (22.01)	298 (33.13)
	91 to 180 days	VTE	17 (0.49)	21 (0.38)	21 (8.76)	16 (5.98)	6 (0.35)	< 5	70 (3.13)	40 (4.45)
		ATE	23 (0.66)	28 (0.51)	31 (12.93)	25 (9.35)	< 5	6 (0.51)	200 (8.93)	112 (12.45)
		HF	61 (1.76)	95 (1.72)	164 (68.38)	115 (43.01)	< 5	5 (0.42)	432 (19.29)	252 (28.02)
181 to 365 days	VTE	11 (0.32)	11 (0.20)	53 (22.10)	22 (8.23)	< 5	< 5	36 (1.61)	13 (1.45)	
	ATE	14 (0.40)	23 (0.42)	56 (23.35)	41 (15.34)	< 5	< 5	124 (5.54)	53 (5.89)	
	HF	54 (1.56)	58 (1.05)	281 (117.17)	199 (74.43)	< 5	6 (0.51)	235 (10.49)	149 (16.57)	
Cohort 2			N = 1,975,726	N = 1,563,569	N = 34,317	N = 4,572	N = 583,399	N = 486,619	N = 433,151	N = 819,590
	0 to 30 days	VTE	345 (1.75)	220 (1.41)	88 (25.64)	8 (17.50)	42 (0.72)	24 (0.49)	404 (9.33)	400 (4.88)
		ATE	74 (0.37)	104 (0.67)	129 (37.59)	5 (10.94)	8 (0.14)	6 (0.12)	345 (7.96)	669 (8.16)
		HF	73 (0.37)	146 (0.93)	393 (114.52)	20 (43.74)	5 (0.09)	13 (0.27)	637 (14.71)	1,331 (16.24)
	31 to 90 days	VTE	87 (0.44)	76 (0.49)	37 (10.78)	< 5	7 (0.12)	9 (0.18)	110 (2.54)	195 (2.38)
		ATE	39 (0.20)	93 (0.59)	33 (9.62)	< 5	7 (0.12)	9 (0.18)	205 (4.73)	444 (5.42)
		HF	50 (0.25)	103 (0.66)	152 (44.29)	10 (21.87)	5 (0.09)	7 (0.14)	274 (6.33)	643 (7.85)
	91 to 180 days	VTE	42 (0.21)	40 (0.26)	27 (7.87)	5 (10.94)	8 (0.14)	< 5	112 (2.59)	125 (1.53)
		ATE	33 (0.17)	43 (0.28)	29 (8.45)	< 5	5 (0.09)	< 5	185 (4.27)	417 (5.09)
		HF	32 (0.16)	69 (0.44)	171 (49.83)	14 (30.62)	< 5	< 5	228 (5.26)	579 (7.06)
181 to 365 days	VTE	18 (0.09)	13 (0.08)	54 (15.74)	< 5	< 5	< 5	37 (0.85)	64 (0.78)	

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		ATE	14 (0.07)	18 (0.12)	62 (18.07)	5 (10.94)	< 5	< 5	112 (2.59)	178 (2.17)
		HF	22 (0.11)	35 (0.22)	286 (83.34)	17 (37.18)	< 5	< 5	111 (2.56)	246 (3.00)
Cohort 3			N = 1,510,401	N = 1,528,031	N = 96,423	N = 24,050	N = 417,996	N = 462,832	N = 869,497	N = 954,232
	0 to 30 days	VTE	268 (1.77)	142 (0.93)	122 (12.65)	8 (3.33)	32 (0.77)	17 (0.37)	425 (4.89)	180 (1.89)
		ATE	34 (0.23)	49 (0.32)	133 (13.79)	11 (4.57)	< 5	12 (0.26)	315 (3.62)	275 (2.88)
		HF	33 (0.22)	38 (0.25)	398 (41.28)	34 (14.14)	< 5	< 5	478 (5.50)	256 (2.68)
	31 to 90 days	VTE	61 (0.40)	46 (0.30)	46 (4.77)	8 (3.33)	< 5	7 (0.15)	120 (1.38)	92 (0.96)
		ATE	14 (0.09)	33 (0.22)	42 (4.36)	13 (5.41)	< 5	8 (0.17)	171 (1.97)	210 (2.20)
		HF	22 (0.15)	26 (0.17)	182 (18.88)	17 (7.07)	< 5	< 5	192 (2.21)	157 (1.65)
	91 to 180 days	VTE	29 (0.19)	26 (0.17)	46 (4.77)	9 (3.74)	5 (0.12)	< 5	101 (1.16)	101 (1.06)
		ATE	8 (0.05)	28 (0.18)	44 (4.56)	8 (3.33)	< 5	< 5	187 (2.15)	206 (2.16)
		HF	12 (0.08)	14 (0.09)	210 (21.78)	18 (7.48)	< 5	< 5	180 (2.07)	138 (1.45)
	181 to 365 days	VTE	< 5	11 (0.07)	79 (8.19)	16 (6.65)	< 5	< 5	45 (0.52)	26 (0.27)
		ATE	< 5	< 5	86 (8.92)	8 (3.33)	< 5	< 5	72 (0.83)	67 (0.70)
		HF	5 (0.03)	< 5	340 (35.26)	36 (14.97)	< 5	< 5	75 (0.86)	44 (0.46)
Cohort 4			N = 2,027,763	N = 2,085,598	N = 147,545	N = 22,245	N = 469,876	N = 550,437	N = 1,061,634	N = 880,950
	0 to 30 days	VTE	337 (1.66)	50 (0.24)	120 (8.13)	< 5	36 (0.77)	11 (0.20)	388 (3.65)	98 (1.11)
		ATE	26 (0.13)	8 (0.04)	121 (8.20)	10 (4.50)	< 5	< 5	268 (2.52)	95 (1.08)
		HF	28 (0.14)	< 5	370 (25.08)	18 (8.09)	< 5	< 5	430 (4.05)	75 (0.85)
	31 to 90 days	VTE	59 (0.29)	22 (0.11)	46 (3.12)	< 5	6 (0.13)	< 5	111 (1.05)	49 (0.56)
		ATE	12 (0.06)	9 (0.04)	40 (2.71)	< 5	< 5	< 5	142 (1.34)	76 (0.86)
		HF	14 (0.07)	9 (0.04)	167 (11.32)	16 (7.19)	< 5	< 5	160 (1.51)	47 (0.53)
	91 to 180 days	VTE	26 (0.13)	10 (0.05)	46 (3.12)	9 (4.05)	< 5	< 5	91 (0.86)	60 (0.68)
		ATE	< 5	6 (0.03)	33 (2.24)	12 (5.39)	< 5	< 5	153 (1.44)	90 (1.02)
		HF	10 (0.05)	< 5	187 (12.67)	13 (5.84)	< 5	< 5	172 (1.62)	55 (0.62)
	181 to 365 days	VTE	< 5	< 5	80 (5.42)	11 (4.94)	< 5	< 5	48 (0.45)	12 (0.14)

Cohort	Time window	Outcome	AURUM		CORIVA		GOLD		SIDIAP	
			Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
		ATE	< 5	< 5	72 (4.88)	10 (4.50)	< 5	< 5	53 (0.50)	28 (0.32)
		HF	< 5	< 5	312 (21.15)	15 (6.74)	< 5	< 5	61 (0.57)	15 (0.17)

296

297

The 4 cohorts represent vaccine rollout periods.

298

VTE = Venous thromboembolism (Deep vein thrombosis + Pulmonary embolism), ATE = Arterial thromboembolism (Ischemic stroke + Transient ischemic attack + Myocardial infarction), HF =

299

Heart failure

300 Results from calibrated estimates pooled in meta-analysis across cohorts and databases are
301 shown in Figure 2.

302 Protective effects of vaccination are observed against acute post COVID-19 VTE, DVT, and PE:
303 meta-analytic sHR of 0.34 (95% CI, 0.27-0.44); 0.51 (0.42-0.62); and 0.30 (0.22-0.41)
304 respectively. The protective effects persisted for subacute VTE: sHR of 0.58 (0.48-0.69), 0.64
305 (0.50-0.82) and 0.54 (0.41-0.72) for 31-90, 91-180, and 181-365 days post COVID-19,
306 respectively. Protection effects of vaccine against these outcomes were observed across
307 databases and cohorts, see Supplementary Figures S16-24.

308 Similarly, the risk of ATE, IS and MI in the acute phase after infection was reduced in the
309 vaccinated, sHR of 0.62 (0.49-0.77), 0.63 (0.45-0.90), and 0.71 (0.58-0.85) respectively.

310 Protection persisted for subacute ATE and IS in the 181-365 days post COVID-19 (sHR of 0.68
311 (0.55-0.84) and 0.70 (0.51-0.96)), and no effect was seen in the 30-180 days window.

312 Vaccination effect on post COVID-19 TIA was only seen in the 181-365 days, sHR of 0.56
313 (0.37- 0.86). Supplementary Figures S25-33 show database- and cohort-specific estimates
314 for ATE related complications.

315 Risk of post COVID-19 cardiac complications was reduced in vaccinated individuals. Meta-
316 analytic estimates in the acute phase showed sHR of 0.58 (0.50-0.70) for HF, 0.51 (0.34-0.77)
317 for MP, and 0.63 (0.44, 0.89) for VACA. Protective effects persisted for subacute post COVID-
318 19 HF: sHR 0.71 (0.59-0.85) for 31-90 days, 0.68 (0.56-0.82) for 91-180 days, and 0.57 (0.44-
319 0.72) for 181-365 days. For subacute MP, risk was only lowered in the 31-90 days post
320 infection, sHR 0.55 (0.31-0.99), and no effect was seen for subacute VACA. Protection
321 against post COVID-19 HS was only seen in the 91-180 days after infection, s, of 0.54 (0.29-

322 0.99). Database- and cohort-specific results for these cardiac diseases are in Supplementary

323 Figures S34-42.


324 Stratified analyses by vaccine brand showed similar associations, except for ChAdOx1 which

325 was not associated with reduced VTE risk in the subacute window. Sensitivity analyses were

326 consistent with main results, see Supplementary Figures S8-15.

327
328

Figure 2: Forest plots for vaccine effectiveness (any COVID-19 vaccine), meta-analysis across cohorts and databases. Dashed line represents a level of heterogeneity $I^2 > 0.4$.




329

330

VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Haemorrhagic stroke

331 Figure 3 shows the results of comparative effects of BNT162b2 vs ChAdOx1, based on UK
332 data. Meta-analytic estimates favoured BNT162b2 (sHR of 0.66 (0.46, 0.93)) for VTE in the 0-
333 30 days after infection, but no differences were seen for subacute VTE or for any of the
334 other outcomes. Results from sensitivity analyses, database- and cohort-specific estimates
335 were in line with the main approach, see Supplementary Figures S43-53.

336 **Figure 3: Forest plots for comparative vaccine effect (BNT162b2 vs. ChAdOx1), meta-analysis across cohorts and databases.**



337

338 VTE = Venous thromboembolism, ATE = Arterial thromboembolism, CD + HS = Cardiac diseases and Haemorrhagic stroke

339 **Discussion**

340 **Key findings**

341 Our analyses showed a substantial reduction of risk (38-66%) for thromboembolic and
342 cardiac events in the acute phase of COVID-19 associated with vaccination. This finding was
343 consistent across four databases and three different European countries. Risks for subacute
344 post COVID-19 VTE and HF were also reduced, but to a lesser extent (29-46%).

345 The risks of post COVID-19 ATE, MP, and VACA were also reduced in vaccinated persons, but
346 only in the acute phase.

347 **Results in context**

348 The relationship between SARS-CoV-2 infection, COVID-19 vaccines, and thromboembolic
349 and/or cardiac complications is tangled. Some large studies have found an increased risk of
350 VTE and ATE following both ChAdOx1 and BNT162b2 vaccination (17,43). However, other
351 studies have not identified such risk (44). It is worth noting that an elevated risk of VTE has
352 also been reported among patients with COVID-19, and its occurrence can lead to poor
353 prognosis and mortality (45–47). Similarly, several observational studies have found an
354 association between COVID-19 mRNA vaccination and a short-term increased risk of
355 myocarditis, particularly among younger male individuals (13–16,48–50). For instance, a self-
356 controlled case series study conducted in England revealed about 30% increased risk of
357 hospital admission due to myocarditis within 28 days following both ChAdOx1 and
358 BNT162b2 vaccines. However, this same study also found a 9-fold higher risk for myocarditis
359 following a positive SARS-CoV-2 test, clearly offsetting the observed post-vaccine risk.

360 COVID-19 vaccines have demonstrated high efficacy and effectiveness in preventing
361 infection and reducing the severity of acute-phase infection. However, with the emergence
362 of newer variants of the virus, such as the Omicron variant (51), and the waning protective
363 effect of the vaccine over time (52), there is a growing interest in understanding whether the
364 vaccine can also reduce the risk of complications after breakthrough infections. Our study
365 demonstrates that vaccination may help mitigate the risk of thromboembolic and cardiac
366 events associated with SARS-CoV-2, including breakthrough infections.

367 Recent studies suggested that COVID-19 vaccination could potentially protect against acute
368 post COVID-19 cardiac and thromboembolic events (22–24). For example, in a large
369 prospective cohort study, Xie et. al (2022) (22) found the risk of VTE after SARS-CoV-2
370 infection was largely attenuated in the fully vaccinated ambulatory patients (about 21-fold
371 and 6-fold after non-vaccinated and breakthrough infection, respectively).

372 While the effect of vaccination on subacute post COVID-19 conditions has been studied,
373 (23,24,53–59), there has been limited reporting on the condition-specific risks associated
374 with COVID-19, even though the prognosis for different complications can vary significantly.

375 In line with previous studies, our findings suggest a potential benefit of vaccination in
376 reducing the risk of post COVID-19 thromboembolic and cardiac complications. We included
377 broader populations, estimated the risk in both acute and subacute infection phases and
378 replicated these using four large independent observational databases. By pooling results
379 across different settings, we provided the most up-to-date and robust evidence on this topic.

380 **Strengths and limitations**

381 The study has several strengths. Our multinational study covering different healthcare
382 systems and setting showed consistent results across all databases, which highlights the

383 robustness and replicability of our findings. All databases had complete recordings of
384 vaccination status (date and brand). Algorithms to identify study outcomes were used in
385 previous published network studies, including regulatory-funded research (6,8,19,31). The
386 staggered cohort design and methods used are yet another strength of our study, as recent
387 research has demonstrated the validity of this design to minimise bias (35).

388 Our study also has limitations. First, the use of real-world data comes with inherent
389 limitations including data quality issues and risk of confounding (60). To address these
390 limitations, we employed state-of-the-art methods, including large-scale propensity score
391 weighting and calibration of effect estimates using NCO (35,41). A recent study (61) has
392 demonstrated that methodologically sound observational studies based on routinely
393 collected data can produce similar results to clinical trials. Another limitation is potential
394 misclassification: Asymptomatic and mild COVID-19 infections may have not been recorded
395 and post COVID-19 outcomes of interest may be under-recorded in primary care databases
396 (CPRD AURUM and GOLD) without hospital linkage. However, results in SIDIAP and CORIVA
397 which include secondary care data were similar.

398 **Conclusions**

399 Vaccination against SARS-CoV-2 substantially reduced the risk of acute post COVID-19
400 thromboembolic and cardiac complications, likely through a reduction in the severity of
401 COVID-19 disease due to vaccine-induced immunity. These protective effects lasted for up to
402 one year for post COVID-19 VTE, but not clearly for other complications. Further research is
403 needed on the possible waning of these protective effects over time, and on the impact of
404 booster vaccination to regain these potential benefits.

405 **References**

- 406 1. Wu N, Joyal-Desmarais K, Ribeiro PAB, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term
407 effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in
408 adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to
409 December, 2022. *Lancet Respir Med*. 2023 May;11(5):439–52.
- 410 2. Lau JJ, Cheng SMS, Leung K, Lee CK, Hachim A, Tsang LCH, et al. Real-world COVID-19 vaccine
411 effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.
412 *Nat Med*. 2023 Feb 18;29(2):348–57.
- 413 3. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD, et al. Impact of
414 vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nat Med*. 2021 Aug
415 9;27(8):1370–8.
- 416 4. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in
417 health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against
418 infection (SIREN): a prospective, multicentre, cohort study. *The Lancet*. 2021
419 May;397(10286):1725–35.
- 420 5. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity
421 of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha
422 SARS-CoV-2 variants in the United States: prospective observational study. *BMJ*. 2022 Mar
423 9;e069761.
- 424 6. Burn E, Li X, Delmestri A, Jones N, Duarte-Salles T, Reyes C, et al. Thrombosis and
425 thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United
426 Kingdom. *Nat Commun*. 2022 Nov 23;13(1):7167.
- 427 7. Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous
428 thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-
429 AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. *BMJ*. 2021
430 May 5;n1114.
- 431 8. Li X, Burn E, Duarte-Salles T, Yin C, Reich C, Delmestri A, et al. Comparative risk of thrombosis
432 with thrombocytopenia syndrome or thromboembolic events associated with different covid-
433 19 vaccines: international network cohort study from five European countries and the US.
434 *BMJ*. 2022 Oct 26;e071594.

- 435 9. Simpson CR, Shi T, Vasileiou E, Katikireddi S V., Kerr S, Moore E, et al. First-dose ChAdOx1 and
436 BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic
437 events in Scotland. *Nat Med.* 2021 Jul 9;27(7):1290–7.
- 438 10. Lee E, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, et al. Thrombocytopenia
439 following Pfizer and Moderna SARS-CoV-2 vaccination. *Am J Hematol.* 2021 May 9;96(5):534–
440 7.
- 441 11. Abraham N, Spruin S, Rossi T, Fireman B, Zafack J, Blaser C, et al. Myocarditis and/or
442 pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of
443 BNT162b2 and mRNA-1273 vaccines. *Vaccine.* 2022 Jul 30;40(32):4663–71.
- 444 12. Lai FTT, Li X, Peng K, Huang L, Ip P, Tong X, et al. Carditis After COVID-19 Vaccination With a
445 Messenger RNA Vaccine and an Inactivated Virus Vaccine. *Ann Intern Med.* 2022
446 Mar;175(3):362–70.
- 447 13. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of
448 myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or
449 SARS-CoV-2 infection. *Nat Med.* 2022 Feb 14;28(2):410–22.
- 450 14. Husby A, Hansen JV, Fosbøl E, Thiesson EM, Madsen M, Thomsen RW, et al. SARS-CoV-2
451 vaccination and myocarditis or myopericarditis: population based cohort study. *BMJ.* 2021
452 Dec 16;e068665.
- 453 15. Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. SARS-CoV-2
454 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. *JAMA Cardiol.*
455 2022 Jun 1;7(6):600.
- 456 16. Simone A, Herald J, Chen A, Gulati N, Shen AYJ, Lewin B, et al. Acute Myocarditis Following
457 COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. *JAMA Intern Med.* 2021 Dec
458 1;181(12):1668.
- 459 17. Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of
460 thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive
461 testing: self-controlled case series study. *BMJ.* 2021 Aug 26;n1931.
- 462 18. Voss EA, Shoaibi A, Yin Hui Lai L, Blacketer C, Alshammari T, Makadia R, et al. Contextualising
463 adverse events of special interest to characterise the baseline incidence rates in 24 million
464 patients with COVID-19 across 26 databases: a multinational retrospective cohort study.
465 *EClinicalMedicine.* 2023 Apr;58:101932.

- 466 19. Burn E, Duarte-Salles T, Fernandez-Bertolin S, Reyes C, Kostka K, Delmestri A, et al. Venous or
467 arterial thrombosis and deaths among COVID-19 cases: a European network cohort study.
468 *Lancet Infect Dis*. 2022 Aug;22(8):1142–52.
- 469 20. Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S, et al. Association of COVID-19 With
470 Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48
471 Million Adults in England and Wales. *Circulation*. 2022 Sep 20;146(12):892–906.
- 472 21. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nat Med*. 2022
473 Mar 7;28(3):583–90.
- 474 22. Xie J, Prats-Urbe A, Feng Q, Wang Y, Gill D, Paredes R, et al. Clinical and Genetic Risk Factors
475 for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19. *JAMA*
476 *Intern Med*. 2022 Oct 1;182(10):1063.
- 477 23. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nat Med*. 2022
478 Jul 25;28(7):1461–7.
- 479 24. Kim YE, Huh K, Park YJ, Peck KR, Jung J. Association Between Vaccination and Acute
480 Myocardial Infarction and Ischemic Stroke After COVID-19 Infection. *JAMA*. 2022 Sep
481 6;328(9):887.
- 482 25. Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile:
483 Clinical Practice Research Datalink (CPRD) Aurum. *Int J Epidemiol*. 2019 Dec 1;48(6):1740–
484 1740g.
- 485 26. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data Resource
486 Profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol*. 2015 Jun;44(3):827–36.
- 487 27. García-Gil MDM, Hermosilla E, Prieto-Alhambra D, Fina F, Rosell M, Ramos R, et al.
488 Construction and validation of a scoring system for the selection of high-quality data in a
489 Spanish population primary care database (SIDIAP). *Inform Prim Care*. 2011;19(3):135–45.
- 490 28. Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of
491 applications of the common data model to multiple, disparate observational health
492 databases. *Journal of the American Medical Informatics Association*. 2015 May 1;22(3):553–
493 64.
- 494 29. Martí Català, Núria Mercadé-Besora, Raivo Kolde, Nhung TH Trinh, Elena Roel, Edward Burn,
495 et al. The Effectiveness of COVID-19 Vaccines to Prevent Long COVID Symptoms: Staggered
496 Cohort Analyses of Data from the UK, Spain, and Estonia. SSRN.

- 497 30. Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S, et al. Association of COVID-19 With
498 Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48
499 Million Adults in England and Wales. *Circulation*. 2022 Sep 20;146(12):892–906.
- 500 31. Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the
501 background incidence rates of adverse events of special interest for covid-19 vaccines in eight
502 countries: multinational network cohort study. *BMJ*. 2021 Jun 14;n1435.
- 503 32. Prieto-Alhambra D, Kostka K, Duarte-Salles T, Prats-Urbe A, Sena A, Pistillo A, et al. Unraveling
504 COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS. *Res*
505 *Sq*. 2021 Mar 1;
- 506 33. Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding
507 and bias in observational studies. *Epidemiology*. 2010 May;21(3):383–8.
- 508 34. Li X, Lai LYH, Ostropolets A, Arshad F, Tan EH, Casajust P, et al. Bias, precision and timeliness of
509 historical (background) rate comparison methods for vaccine safety monitoring: an empirical
510 multi-database analysis. *Front Pharmacol*. 2021;12:773875.
- 511 35. Català M, Burn E, Rathod-Mistry T, Xie J, Delmestri A, Prieto-Alhambra D, et al. Observational
512 methods for COVID-19 vaccine effectiveness research: a trial emulation and empirical
513 evaluation. *medRxiv [Internet]*. 2022 Jan 1;2022.11.09.22282065. Available from:
514 <http://medrxiv.org/content/early/2022/11/17/2022.11.09.22282065.abstract>
- 515 36. Li F, Morgan KL, Zaslavsky AM. Balancing Covariates via Propensity Score Weighting. *J Am Stat*
516 *Assoc*. 2018 Jan 2;113(521):390–400.
- 517 37. Coronavirus (COVID-19) in the UK [Internet]. [cited 2022 Dec 15]. Available from:
518 <https://coronavirus.data.gov.uk/>
- 519 38. Generalitat de Catalunya. Dades COVID [Internet]. [cited 2022 Jan 15]. Available from:
520 <https://dadescovid.cat/>
- 521 39. Nguyen TL, Collins GS, Spence J, Daurès JP, Devereaux PJ, Landais P, et al. Double-adjustment
522 in propensity score matching analysis: choosing a threshold for considering residual
523 imbalance. *BMC Med Res Methodol*. 2017 Dec 28;17(1):78.
- 524 40. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *J*
525 *Am Stat Assoc*. 1999 Jun;94(446):496–509.

- 526 41. Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval
527 calibration for population-level effect estimation studies in observational healthcare data.
528 *Proceedings of the National Academy of Sciences*. 2018 Mar 13;115(11):2571–7.
- 529 42. Serghiou S, Goodman SN. Random-Effects Meta-analysis. *JAMA*. 2019 Jan 22;321(3):301.
- 530 43. Elkin PL, Brown SH, Resendez S, McCray W, Resnick M, Hall K, et al. COVID-19 vaccination and
531 venous thromboembolism risk in older veterans. *J Clin Transl Sci*. 2023 Feb 1;7(1):e55.
- 532 44. Houghton DE, Wysokinski W, Casanegra AI, Padrnos LJ, Shah S, Wysokinska E, et al. Risk of
533 venous thromboembolism after COVID-19 vaccination. *Journal of Thrombosis and*
534 *Haemostasis*. 2022 Jul;20(7):1638–44.
- 535 45. Katsoularis I, Fonseca-Rodríguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, et al.
536 Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide
537 self-controlled cases series and matched cohort study. *BMJ*. 2022 Apr 6;e069590.
- 538 46. Fang MC, Reynolds K, Tabada GH, Prasad PA, Sung SH, Parks AL, et al. Assessment of the Risk
539 of Venous Thromboembolism in Nonhospitalized Patients With COVID-19. *JAMA Netw Open*.
540 2023 Mar 13;6(3):e232338.
- 541 47. Lee Y, Jehangir Q, Li P, Gudimella D, Mahale P, Lin CH, et al. Venous thromboembolism in
542 COVID-19 patients and prediction model: a multicenter cohort study. *BMC Infect Dis*. 2022
543 Dec 13;22(1):462.
- 544 48. Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. SARS-CoV-2
545 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. *JAMA Cardiol*.
546 2022 Jun 1;7(6):600.
- 547 49. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19
548 Vaccination in a Large Health Care Organization. *New England Journal of Medicine*. 2021 Dec
549 2;385(23):2132–9.
- 550 50. Wong HL, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, et al. Risk of myocarditis and
551 pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims
552 databases. *The Lancet*. 2022 Jun;399(10342):2191–9.
- 553 51. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine
554 Effectiveness against the Omicron (B.1.1.529) Variant. *New England Journal of Medicine*. 2022
555 Apr 21;386(16):1532–46.

- 556 52. Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and
557 effectiveness and side-effects of boosters: a prospective community study from the ZOE
558 COVID Study. *Lancet Infect Dis*. 2022 Jul;22(7):1002–10.
- 559 53. Zisis SN, Durieux JC, Mouchati C, Perez JA, McComsey GA. The Protective Effect of Coronavirus
560 Disease 2019 (COVID-19) Vaccination on Postacute Sequelae of COVID-19: A Multicenter
561 Study From a Large National Health Research Network. *Open Forum Infect Dis*. 2022 Jul
562 4;9(7).
- 563 54. Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine
564 versus no vaccination on symptoms of **patients** with long covid: target trial emulation based
565 on ComPaRe e-cohort. *BMJ Medicine*. 2023 Feb 28;2(1):e000229.
- 566 55. Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long
567 covid: systematic review. *BMJ Medicine*. 2023 Feb;2(1):e000385.
- 568 56. Ioannou GN, Baraff A, Fox A, Shahoumian T, Hickok A, O’Hare AM, et al. Rates and Factors
569 Associated With Documentation of Diagnostic Codes for Long COVID in the National Veterans
570 Affairs Health Care System. *JAMA Netw Open*. 2022 Jul 29;5(7):e2224359.
- 571 57. Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. Association Between
572 BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in
573 Health Care Workers. *JAMA*. 2022 Aug 16;328(7):676.
- 574 58. Brannock MD, Chew RF, Preiss AJ, Hadley EC, Redfield S, McMurry JA, et al. Long COVID risk
575 and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. *Nat*
576 *Commun*. 2023 May 22;14(1):2914.
- 577 59. Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. Risk Factors
578 Associated With Post–COVID-19 Condition. *JAMA Intern Med*. 2023 Mar 23;
- 579 60. Yuan H, Ali MS, Brouwer ES, Girman CJ, Guo JJ, Lund JL, et al. Real-World Evidence: What It Is
580 and What It Can Tell Us According to the International Society for Pharmacoepidemiology
581 (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG). *Clin Pharmacol*
582 *Ther*. 2018 Aug;104(2):239–41.
- 583 61. Wang S V., Schneeweiss S, Franklin JM, Desai RJ, Feldman W, Garry EM, et al. Emulation of
584 Randomized Clinical Trials With Nonrandomized Database Analyses. *JAMA*. 2023 Apr
585 25;329(16):1376.

586

588 **Article Information**

589 **Corresponding author**

590 Prof. Daniel Prieto-Alhambra

591 Botnar Research Centre, Windmill Road, OX3 7LD, Oxford, United Kingdom

592 **Author Contributions:**

593 DPA and AMJ led the conceptualisation of the study with contributions from MC and NMB.

594 AMJ, TDS, ER, AU and NT adapted the study design with respect to the local vaccine rollouts.

595 AD and WM mapped and curated CPRD data. MC and NMB developed code with

596 methodological contributions advice from MTSS and CP. DPA, MC, NT, TDS, HE, XL, CR, and

597 AMJ clinically interpreted the results. NMB, XL, AMJ and DPA wrote the first draft of the

598 manuscript, and all authors read, revised, and approved the last version. DPA and AMJ

599 obtained the funding for this research.

600 **Ethics**

601 The study was approved by the CPRD's Research Data Governance Process, Protocol No

602 21_000557 and the Clinical Research Ethics committee of Fundació Institut Universitari per a

603 la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol) (approval number

604 4R22/133) and the Research Ethics Committee of the University of Tartu (approval No.

605 330/T-10).

606 **Disclosures**

607 DPA's department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis,

608 and UCB Biopharma, the European Medicines Agency and the Innovative Medicines

609 Initiative. His research group has received consultancy fees from Astra Zeneca and UCB
610 Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma
611 have funded or supported training programmes organised by DPA's department. RK's
612 research group has received consultancy fees from AstraZeneca, and the Estonian Ministry
613 of Social Affairs through the RITA CORIVA and RITA MAITT projects. AU reports funding from
614 the European Regional Development Fund (RITA 1/02-120) for her institution. HN reports
615 support from the European Health Data & Evidence Network (EHDEN) project grant,
616 Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968 for
617 harmonization of the Norwegian registry data into OMOP CDM. TDS reports funding from
618 the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No
619 806968 for the institute to map the SIDIAP data to the OMOP CDM. The JU receives support
620 from the European Union's Horizon 2020 research and innovation programme and EFPIA. All
621 other authors declare no conflict of interest.

622 **Funding/Support**

623 The research was supported by the National Institute for Health and Care Research (NIHR)
624 Oxford Biomedical Research Centre (BRC).
625 DPA is funded through a NIHR Senior Research Fellowship (Grant number SRF-2018–11-ST2-
626 004).
627 Funding to perform the study in the SIDIAP database was provided by the Real World
628 Epidemiology (RWEpi) research group at IDIAPJGol.
629 Costs of databases mapping to OMOP CDM were covered by the European Health Data and
630 Evidence Network (EHDEN).

631 **Role of the Funder/Sponsor**

632 The funders had no role in the design and conduct of the study; interpretation of the data;
633 preparation of the manuscript; and decision to submit it for publication.

634 **Data Sharing Statement**

635 CPRD: CPRD data were obtained under the CPRD multi-study license held by the University
636 of Oxford after Research Data Governance (RDG) approval. Direct data sharing is not
637 allowed.

638 SIDIAP: In accordance with current European and national law, the data used in this study is
639 only available for the researchers participating in this study. Thus, we are not allowed to
640 distribute or make publicly available the data to other parties. However, researchers from
641 public institutions can request data from SIDIAP if they comply with certain requirements.
642 Further information is available online ([https://www.sidiap.org/index.php/menu-](https://www.sidiap.org/index.php/menu-solicitudesen/application-procedure)
643 [solicitudesen/application-procedure](https://www.sidiap.org/index.php/menu-solicitudesen/application-procedure)) or by contacting SIDIAP (sidiap@idiapjgol.org).

644 CORIVA: CORIVA data were obtained under the approval of Research Ethics Committee of
645 the University of Tartu and the patient level data sharing is not allowed.

646 **Acknowledgements**

647 This study is based in part on data from the Clinical Practice Research Datalink obtained
648 under license from the UK Medicines and Healthcare products Regulatory Agency. We thank
649 the patients who provided these data, and the NHS who collected the data as part of their
650 care and support. All interpretations, conclusions and views expressed in this publication are
651 those of the authors alone and not necessarily those of CPRD.

652 We would also like to thank the healthcare professionals in the Catalan healthcare system
653 involved in the management of COVID-19 during these challenging times, from primary care
654 to intensive care units; the Institut de Català de la Salut and the Program d'Anàlisi de
655 Dades per a la Recerca i la Innovació en Salut for providing access to the different data
656 sources accessible through SIDIAP.